{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:06:55Z","timestamp":1790856415333,"version":"4.1.0"},"reference-count":58,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,8]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Antithrombotic therapy can prevent recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE). It is, however, associated with an increased risk for major bleeding. This meta-analysis systematically reviewed the evidence regarding the duration of antithrombotic therapy to assess benefits and harms. We systematically searched for randomized controlled trials (RCTs) that compared shorter (3-6\u00a0months) with longer (&amp;gt;6\u00a0months) courses of anticoagulation for the primary treatment of venous thromboembolism (VTE) or that compared discontinued with indefinite antithrombotic therapy for the secondary prevention of VTE. Pairs of reviewers screened the eligible trials and collected data. This study included 22 RCTs (11\u2009617 participants). Pooled estimates showed that, for the primary treatment of unprovoked VTE, VTE provoked by chronic risk factors or transient risk factors, treating patients with a longer course (&amp;gt;6\u00a0months) of anticoagulation, as opposed to a shorter course (3-6\u00a0months), probably reduced recurrent PE (risk ratio [RR], 0.66; 95% confidence interval [CI], 0.42-1.02) and DVT (RR, 0.85; 95%\u00a0CI, 0.63-1.14), but it was associated with increased mortality (RR, 1.43; 95%\u00a0CI, 0.85-2.41) (moderate certainty) and a higher risk for major bleeding (RR, 2.02; 95%\u00a0CI, 1.02-3.98; high certainty). For the secondary prevention of unprovoked VTE and VTE provoked by chronic risk factors, when compared with discontinuing treatment, indefinite anticoagulation therapy was associated with decreased mortality (RR, 0.54; 95%\u00a0CI, 0.36-0.81), a reduction in recurrent PE (RR, 0.25; 95%\u00a0CI, 0.16-0.41) and DVT (RR, 0.15; 95%\u00a0CI, 0.10-0.21), and an increase in the risk for bleeding (RR, 1.98; 95%\u00a0CI, 1.18-3.30), all supported by high certainty. Indefinite antiplatelet therapy may be associated with decreased mortality (RR, 0.95; 95%\u00a0CI: 0.53-1.68; low certainty), probably a reduction in recurrent PE (RR, 0.65; 95%\u00a0CI, 0.41-1.03) and DVT (RR, 0.44; 95%\u00a0CI, 0.17-1.13) (moderate certainty), and may increase the risk for bleeding (RR, 1.28; 95%\u00a0CI, 0.48-3.41; low certainty). In summary, for the primary treatment of all types of VTE, shorter (3-6\u00a0months) duration of anticoagulation is more beneficial. For the secondary prevention of unprovoked VTE or VTE provoked by chronic risk factors, indefinite antithrombotic treatment is more beneficial.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015371","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T15:54:45Z","timestamp":1744127685000},"page":"1742-1761","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Duration of primary\/secondary treatment to prevent recurrent venous thromboembolism: a systematic review and meta-analysis"],"prefix":"10.1182","volume":"9","author":[{"given":"Anqi","family":"Li","sequence":"first","affiliation":[{"name":"1Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Khatib","sequence":"additional","affiliation":[{"name":"2Advocate Aurora Research Institute, Downers Grove, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciane Cruz","family":"Lopes","sequence":"additional","affiliation":[{"name":"3Pharmaceutical Sciences Graduate Course, University of Sorocaba, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fazila","family":"Aloweni","sequence":"additional","affiliation":[{"name":"4Nursing Division, Singapore General Hospital, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Lu","sequence":"additional","affiliation":[{"name":"5Clinical Research and Big Data Laboratory, South China Research Center for Acupuncture and Moxibustion, Medical College of Acu-Moxi and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyong","family":"He","sequence":"additional","affiliation":[{"name":"1Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaming","family":"Wu","sequence":"additional","affiliation":[{"name":"6Zhongshan Hospital of Traditional Chinese Medicine affiliated to Guangzhou University of Chinese Medicine, Zhongshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiming","family":"Zhang","sequence":"additional","affiliation":[{"name":"5Clinical Research and Big Data Laboratory, South China Research Center for Acupuncture and Moxibustion, Medical College of Acu-Moxi and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China"},{"name":"7Affiliated Foshan Hospital of Traditional Chinese Medicine, The Eighth Clinical Medical College, Guangzhou University of Chinese Medicine, Foshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyuan","family":"Tang","sequence":"additional","affiliation":[{"name":"5Clinical Research and Big Data Laboratory, South China Research Center for Acupuncture and Moxibustion, Medical College of Acu-Moxi and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sureka","family":"Pavalagantharajah","sequence":"additional","affiliation":[{"name":"8Department of Pediatrics, McMaster University, Hamilton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigar","family":"Sekercioglu","sequence":"additional","affiliation":[{"name":"9Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada"},{"name":"10Division of Nephrology, Department of Internal Medicine, Health Sciences University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Cuello Garcia","sequence":"additional","affiliation":[{"name":"9Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Koujanian","sequence":"additional","affiliation":[{"name":"11Department of Laboratory Hematology, Laboratory Medicine Program, University Health Network, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0931-7851","authenticated-orcid":false,"given":"Arnav","family":"Agarwal","sequence":"additional","affiliation":[{"name":"9Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean Alexander","family":"Kennedy","sequence":"additional","affiliation":[{"name":"12Department of Medicine, McMaster University, Hamilton, ON, Canada"},{"name":"13Department of Laboratory Hematology, Laboratory Medicine Program, University Health Network, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Neumann","sequence":"additional","affiliation":[{"name":"9Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada"},{"name":"14School of Medicine, Universidad San Sebasti\u00e1n, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8512-9043","authenticated-orcid":false,"given":"Sam","family":"Schulman","sequence":"additional","affiliation":[{"name":"15Thrombosis and Atherosclerosis Research Institute, McMaster University Medical Centre, Hamilton, Canada"},{"name":"16Department of Obstetrics and Gynaecology, I.M. Sechenov First Moscow State Medical University, Moskva, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-1650","authenticated-orcid":false,"given":"Wojtek","family":"Wiercioch","sequence":"additional","affiliation":[{"name":"9Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Rada","sequence":"additional","affiliation":[{"name":"17Epistemonikos Foundation, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Peseski","sequence":"additional","affiliation":[{"name":"18Division of Hematology, Department of Medicine, Duke University, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6193-4585","authenticated-orcid":false,"given":"Thomas L.","family":"Ortel","sequence":"additional","affiliation":[{"name":"19Division of Hematology, Department of Medicine, and Department of Pathology, Duke University, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Qing","family":"Zhang","sequence":"additional","affiliation":[{"name":"9Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada"},{"name":"20Center for Evidence Based Integrative Medicine\u2013Clarity Collaboration, Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"2025041412314715300_bib1","first-page":"0208","article-title":"Thromboembolism","volume":"3","author":"McManus","year":"2011","journal-title":"BMJ Clin Evid."},{"issue":"4","key":"2025041412314715300_bib2","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2007.02450.x","article-title":"Incidence and mortality of venous thrombosis: a population-based study","volume":"5","author":"Naess","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"issue":"8","key":"2025041412314715300_bib3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","article-title":"Epidemiology of venous thromboembolism","volume":"12","author":"Heit","year":"2015","journal-title":"Nat Rev Cardiol"},{"issue":"9383","key":"2025041412314715300_bib4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0140-6736(03)14111-6","article-title":"Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study","volume":"362","author":"Baglin","year":"2003","journal-title":"Lancet"},{"issue":"19","key":"2025041412314715300_bib5","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1001\/jama.293.19.2352","article-title":"Thrombophilia, clinical factors, and recurrent venous thrombotic events","volume":"293","author":"Christiansen","year":"2005","journal-title":"JAMA"},{"issue":"6","key":"2025041412314715300_bib6","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/archinte.160.6.769","article-title":"Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors","volume":"160","author":"Hansson","year":"2000","journal-title":"Arch Intern Med"},{"issue":"6","key":"2025041412314715300_bib7","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/archinte.160.6.761","article-title":"Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch Intern Med"},{"issue":"1","key":"2025041412314715300_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-125-1-199607010-00001","article-title":"The long-term clinical course of acute deep venous thrombosis","volume":"125","author":"Prandoni","year":"1996","journal-title":"Ann Intern Med"},{"issue":"12","key":"2025041412314715300_bib9","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1056\/NEJM199903253401209","article-title":"Venous thrombosis as a chronic disease","volume":"340","author":"Schafer","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2025041412314715300_bib10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3324\/haematol.10516","article-title":"The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients","volume":"92","author":"Prandoni","year":"2007","journal-title":"Haematologica"},{"issue":"19","key":"2025041412314715300_bib11","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"key":"2025041412314715300_bib12","author":"Higgins","year":"2019"},{"issue":"10","key":"2025041412314715300_bib13","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"4","key":"2025041412314715300_bib14","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"issue":"9","key":"2025041412314715300_bib15","doi-asserted-by":"crossref","first-page":"578","DOI":"10.7326\/0003-4819-152-9-201005040-00008","article-title":"Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism","volume":"152","author":"Carrier","year":"2010","journal-title":"Ann Intern Med"},{"issue":"19","key":"2025041412314715300_bib16","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1001\/archinternmed.2010.367","article-title":"Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review","volume":"170","author":"Iorio","year":"2010","journal-title":"Arch Intern Med"},{"issue":"4","key":"2025041412314715300_bib17","first-page":"834","article-title":"Dynamics of case-fatality rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism","volume":"110","author":"Lecumberri","year":"2013","journal-title":"Thromb Haemost"},{"key":"2025041412314715300_bib18","doi-asserted-by":"crossref","first-page":"l4363","DOI":"10.1136\/bmj.l4363","article-title":"Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis","volume":"366","author":"Khan","year":"2019","journal-title":"BMJ"},{"issue":"7650","key":"2025041412314715300_bib19","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"5","key":"2025041412314715300_bib20","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.0954-6820.1985.tb03261.x","article-title":"The duration of oral anticoagulation after deep vein thrombosis. A randomized study","volume":"217","author":"Schulman","year":"1985","journal-title":"Acta Med Scand"},{"issue":"3","key":"2025041412314715300_bib21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2008-01-131656","article-title":"Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study","volume":"112","author":"Siragusa","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2025041412314715300_bib22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.7326\/0003-4819-139-1-200307010-00008","article-title":"Extended oral anticoagulant therapy after a first episode of pulmonary embolism","volume":"139","author":"Agnelli","year":"2003","journal-title":"Ann Intern Med"},{"issue":"3","key":"2025041412314715300_bib23","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1056\/NEJM200107193450302","article-title":"Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin optimal duration Italian trial investigators","volume":"345","author":"Agnelli","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2025041412314715300_bib24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1024\/0301-1526.38.3.238","article-title":"The development of persistent thrombotic masses in patients with deep venous thrombosis randomized to long-term anticoagulation treatment","volume":"38","author":"Vitovec","year":"2009","journal-title":"Vasa"},{"issue":"11","key":"2025041412314715300_bib25","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJMoa067703","article-title":"Extended prophylaxis of venous thromboembolism with idraparinux","volume":"357","author":"Buller","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2025041412314715300_bib26","first-page":"848","article-title":"Anticoagulation period in idiopathic venous thromboembolism. How long is enough?","volume":"25","author":"Farraj","year":"2004","journal-title":"Saudi Med J"},{"issue":"1","key":"2025041412314715300_bib27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jama.2015.7046","article-title":"Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: the PADIS-PE randomized clinical trial","volume":"314","author":"Couturaud","year":"2015","journal-title":"JAMA"},{"issue":"7","key":"2025041412314715300_bib28","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.3324\/haematol.2018.210971","article-title":"Six months versus two years of oral anticoagulation after a first episode of unprovoked deep-vein thrombosis. The PADIS-DVT randomized clinical trial","volume":"104","author":"Couturaud","year":"2019","journal-title":"Haematologica"},{"issue":"5","key":"2025041412314715300_bib29","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00277-008-0626-1","article-title":"6 versus 30\u00a0months anticoagulation for recurrent venous thrombosis in patients with high factor VIII","volume":"88","author":"Eischer","year":"2009","journal-title":"Ann Hematol"},{"issue":"9","key":"2025041412314715300_bib30","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/000331979304400904","article-title":"Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings","volume":"44","author":"Belcaro","year":"1993","journal-title":"Angiology"},{"issue":"18","key":"2025041412314715300_bib31","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa030104","article-title":"Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran","volume":"349","author":"Schulman","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2025041412314715300_bib32","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"2025041412314715300_bib33","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1056\/NEJMoa054444","article-title":"D-dimer testing to determine the duration of anticoagulation therapy","volume":"355","author":"Palareti","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"2025041412314715300_bib34","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa035029","article-title":"Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism","volume":"348","author":"Ridker","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2025041412314715300_bib35","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199903253401201","article-title":"A\u00a0comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism","volume":"340","author":"Kearon","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2025041412314715300_bib36","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2025041412314715300_bib37","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199702063360601","article-title":"The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group","volume":"336","author":"Schulman","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2025041412314715300_bib38","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"2025041412314715300_bib39","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMoa1114238","article-title":"Aspirin for preventing the recurrence of venous thromboembolism","volume":"366","author":"Becattini","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"2025041412314715300_bib40","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMoa1210384","article-title":"Low-dose aspirin for preventing recurrent venous thromboembolism","volume":"367","author":"Brighton","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2025041412314715300_bib41","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/bjh.16275","article-title":"A\u00a0randomised controlled trial of extended anticoagulation treatment versus standard treatment for the prevention of recurrent venous thromboembolism (VTE) and post-thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (the ExACT study)","volume":"188","author":"Bradbury","year":"2020","journal-title":"Br J Haematol"},{"issue":"7","key":"2025041412314715300_bib42","doi-asserted-by":"crossref","first-page":"949","DOI":"10.7326\/M22-3559","article-title":"Indefinite anticoagulant therapy for first unprovoked venous thromboembolism: a cost-effectiveness study","volume":"176","author":"Khan","year":"2023","journal-title":"Ann Intern Med"},{"key":"2025041412314715300_bib43","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jclinepi.2017.10.012","article-title":"Association between prospective registration and overall reporting and methodological quality of systematic reviews: a meta-epidemiological study","volume":"93","author":"Ge","year":"2018","journal-title":"J\u00a0Clin Epidemiol"},{"key":"2025041412314715300_bib44","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.thromres.2016.01.005","article-title":"Extended anticoagulation and mortality in venous thromboembolism. A meta-analysis of six randomized trials","volume":"139","author":"Bova","year":"2016","journal-title":"Thromb Res"},{"issue":"3","key":"2025041412314715300_bib45","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/jth.12501","article-title":"Major bleeding during secondary prevention of venous thromboembolism in patients who have completed anticoagulation: a systematic review and meta-analysis","volume":"12","author":"Castellucci","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"issue":"5","key":"2025041412314715300_bib46","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/1074248415575154","article-title":"Case fatality rates of recurrent thromboembolism and bleeding in patients receiving direct oral anticoagulants for the initial and extended treatment of venous thromboembolism: a systematic review","volume":"20","author":"Gomez-Outes","year":"2015","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"key":"2025041412314715300_bib47","doi-asserted-by":"crossref","first-page":"540386","DOI":"10.1155\/2010\/540386","article-title":"Different finite durations of anticoagulation and outcomes following idiopathic venous thromboembolism: a meta-analysis","volume":"2010","author":"Holley","year":"2010","journal-title":"Thrombosis"},{"issue":"11","key":"2025041412314715300_bib48","doi-asserted-by":"crossref","first-page":"e0143252","DOI":"10.1371\/journal.pone.0143252","article-title":"Extended anticoagulant and aspirin treatment for the secondary prevention of thromboembolic disease: a systematic review and meta-analysis","volume":"10","author":"Marik","year":"2015","journal-title":"PLoS One"},{"issue":"8","key":"2025041412314715300_bib49","first-page":"CD001367","article-title":"Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism","volume":"2014","author":"Middeldorp","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"2025041412314715300_bib50","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1001\/jama.294.6.706","article-title":"Duration of anticoagulation following venous thromboembolism: a meta-analysis","volume":"294","author":"Ost","year":"2005","journal-title":"JAMA"},{"issue":"5","key":"2025041412314715300_bib51","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1046\/j.1365-2796.2000.00631.x","article-title":"Comparison of long versus short duration of anticoagulant therapy after a first episode of venous thromboembolism: a meta-analysis of randomized, controlled trials","volume":"247","author":"Pinede","year":"2000","journal-title":"J\u00a0Intern Med"},{"issue":"10","key":"2025041412314715300_bib52","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.clinthera.2014.06.033","article-title":"Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach","volume":"36","author":"Rollins","year":"2014","journal-title":"Clin Ther"},{"issue":"11","key":"2025041412314715300_bib53","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s40265-013-0082-7","article-title":"Efficacy and safety of new oral anticoagulants for extended treatment of venous thromboembolism: systematic review and meta-analyses of randomized controlled trials","volume":"73","author":"Sardar","year":"2013","journal-title":"Drugs"},{"issue":"13","key":"2025041412314715300_bib54","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1161\/CIRCULATIONAHA.114.008828","article-title":"Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration","volume":"130","author":"Simes","year":"2014","journal-title":"Circulation"},{"issue":"4","key":"2025041412314715300_bib55","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.thromres.2015.07.022","article-title":"Safety and efficacy of direct oral anticoagulants compared to warfarin for extended treatment of venous thromboembolism -a systematic review and meta-analysis","volume":"136","author":"Sindet-Pedersen","year":"2015","journal-title":"Thromb Res"},{"issue":"5","key":"2025041412314715300_bib56","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.thromres.2015.02.032","article-title":"Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: a network meta-analysis","volume":"135","author":"Sobieraj","year":"2015","journal-title":"Thromb Res"},{"issue":"9","key":"2025041412314715300_bib57","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/ajh.20691","article-title":"Duration of vitamin K antagonist therapy for venous thromboembolism: a systematic review of the literature","volume":"81","author":"Streiff","year":"2006","journal-title":"Am J Hematol"},{"issue":"10","key":"2025041412314715300_bib58","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/bloodadvances.2020001768","article-title":"Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences","volume":"4","author":"Wiercioch","year":"2020","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/7\/1742\/2367411\/blooda_adv-2024-015371-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/7\/1742\/2367411\/blooda_adv-2024-015371-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T12:32:00Z","timestamp":1744633920000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/7\/1742\/534834\/Duration-of-primary-secondary-treatment-to-prevent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,4,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015371","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]}}}